SARALASIN manufacturers
- Saralasin
-
- $1.00
-
2024-08-27
- CAS:34273-10-4
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 20T
- Saralasin
-
-
2020-05-10
- CAS:34273-10-4
- Min. Order: 1KG
- Purity: 99.0%
- Supply Ability: 500 MT
- SARALASIN
-
- $1.00
-
2019-08-09
- CAS:34273-10-4
- Min. Order: 1KG
- Purity: 98%
- Supply Ability: 1kg,5kg,100kg
|
| | SARALASIN Basic information |
| Product Name: | SARALASIN | | Synonyms: | (Sar1,Val5,Ala8)-Angiotensin II
Saralasin;[Sar1, Val5, Ala8]-Angiotensin II acetate salt hydrate
;SAR-ARG-VAL-TYR-VAL-HIS-PRO-ALA-OH;SAR-ARG-VAL-TYR-VAL-HIS-PRO-ALA;[SAR1,VAL5, ALA8]ANGIOTENSIN II, HUMAN;(SAR1,VAL5,ALA8)-ANGIOTENSIN II;SARALASIN;[sar1, val5, ala8]-angiotensin ii acetate hydrate | | CAS: | 34273-10-4 | | MF: | C42H65N13O10 | | MW: | 912.05 | | EINECS: | | | Product Categories: | Angiotensin | | Mol File: | 34273-10-4.mol |  |
| | SARALASIN Chemical Properties |
| density | 1.42±0.1 g/cm3(Predicted) | | storage temp. | −20°C | | form | powder | | pka | 3.70±0.10(Predicted) | | Sequence | {Sar}-Arg-Val-Tyr-Val-His-Pro-Ala | | CAS DataBase Reference | 34273-10-4 |
| | SARALASIN Usage And Synthesis |
| Uses | Antihypertensive. | | Uses | Saralasin are angiotensin II receptor agonists. | | Definition | ChEBI: Saralasin is an oligopeptide. | | Brand name | Sarenin (Procter & Gamble). | | in vivo | Saralasin (intravenous injection, 5-50 μg/kg, a single dose) ameliorates the oxidative stress and tissue injury in cerulein-induced pancreatitis[5].
Saralasin (subcutaneous injection, 10 and 30 mg/kg, a single dose) increases serum renin activity (SRA) in normal, conscious rats, without markedly altering blood pressure or heart rate[6]. | Animal Model: | Cerulein-induced acute pancreatitis rats model[5] | | Dosage: | 5, 10, 20, and 50 μg/kg, a single dose. | | Administration: | Intravenous injection | | Result: | Restored the pancreatic morphological characteristics to the control level.
Reduced pancreatic injury and suppressed the glutathione depletion induced by cerulean.
|
| Animal Model: | Male Sprague-Dawley rats[6] | | Dosage: | 10 and 30 mg/kg, a single dose. | | Administration: | Subcutaneous injection | | Result: | Stimulated renin release without altering blood pressure or heart rate at the time of measuring serum renin levels 20 minutes after injection. |
|
| | SARALASIN Preparation Products And Raw materials |
|